Evidence map›Paper›PMID 36639708›Full record

ArticleMolecular brain2023

Tyrosine phosphatase STEP

Deonne Taylor, Andrew Kneynsberg, Marloes van Roijen, Jürgen Götz

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular brain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Deonne TaylorClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St. Lucia Campus, Brisbane, QLD, Australia.
Andrew KneynsbergClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St. Lucia Campus, Brisbane, QLD, Australia.
Marloes van RoijenNew South Wales Brain Bank, The University of Sydney, NSW, Sydney, Australia.
Jürgen GötzClem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, St. Lucia Campus, Brisbane, QLD, Australia. j.goetz@uq.edu.au.ORCID 0000-0001-8501-7896
The University of Queensland · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synaptic degeneration is a precursor of synaptic and neuronal loss in neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal dementia with tau pathology (FTD-tau), a group of primary tauopathies. A critical role in this degenerative process is assumed by enzymes such as the kinase Fyn and its counterpart, the phosphatase striatal-enriched tyrosine phosphatase 61 (STEP

Indexed as

Alzheimer DiseaseFrontotemporal DementiaProtein Tyrosine Phosphatases, Non-ReceptorAmyloidAmyloid beta-PeptidesAnimalsDisease Models, AnimalHumansMiceMice, TransgenicProtein Tyrosine Phosphatasestau ProteinsTyrosineAmyloidAmyloid beta-PeptidesProtein Tyrosine PhosphatasesProtein Tyrosine Phosphatases, Non-ReceptorPTPN5 protein, humanPtpn5 protein, mousetau ProteinsTyrosineAlzheimer’s diseaseAmyloid-βFrontotemporal dementiaMicrotubule-associated protein tauStriatal-enriched tyrosine phosphatase 61 (STEP61)Transgenic mice

Identifiers

PMID36639708
PMCPMC9840288
OpenAlexW4315874372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.